Hyperinflammation and the utility of immunomodulatory medications in chil‐ dren with COVID-19

dc.creatorTanner, Tamara
dc.creatorWahezi, Dawn M.
dc.date.accessioned2020-08-10T19:37:16Z
dc.date.accessioned2022-09-23T18:37:17Z
dc.date.available2020-08-10T19:37:16Z
dc.date.available2022-09-23T18:37:17Z
dc.date.created2020-08-10T19:37:16Z
dc.identifier1526-0542
dc.identifierhttps://doi.org/10.1016/j.prrv.2020.07.003
dc.identifierhttp://hdl.handle.net/20.500.12010/11788
dc.identifierhttps://doi.org/10.1016/j.prrv.2020.07.003
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3504289
dc.description.abstractThe rapid spread of SARS-CoV-2 infection globally coupled with the relatively high case-fatality rate has led to immediate need for therapeutic intervention to prevent and treat COVID-19 disease. There is accumulating evidence that morbidity and mortality in COVID-19 may be exacerbated by a dysregulated host immune response resulting in significant hyperinflammation and cytokine release. The aim of this review is to describe the basis for the immune dysregulation caused by SARS-CoV-2 infection and to examine current investigations into immunomodulatory therapies aimed at targeting the excessive host immune response.
dc.publisherPaediatric Respiratory Reviews
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.rightsAcceso restringido
dc.sourcereponame:Expeditio Repositorio Institucional UJTL
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozano
dc.subjectCOVID-19
dc.subjectMedications in children
dc.subjectHyperinflammation
dc.titleHyperinflammation and the utility of immunomodulatory medications in chil‐ dren with COVID-19


Este ítem pertenece a la siguiente institución